Syndax raises $80M in series C

Syndax Pharmaceuticals Inc. (Waltham, Mass.) raised $80 million in a series C round led by Fidelity and Delos Capital. EcoR1 Capital, OrbiMed, Jennison Associates, Tavistock Life Sciences, Arrowpoint Partners, Cormorant Asset Management, BioMed Ventures and undisclosed mutual funds also participated, as did existing investors Domain Associates, MPM Capital, RusnanoMedInvest and Forward Ventures.

Syndax's lead program is entinostat, which is in the Phase III E2112 study to treat advanced estrogen receptor-positive breast cancer in postmenopausal women. ECOG-ACRIN Cancer Research Group began the study last year. The oral histone deacetylase ( HDAC) inhibitor has breakthrough therapy designation in the indication. ...